Storz & Bickel-Tetra Collaboration on Investigational Inhaled Medical Cannabis Product Moves Forward

Storz & Bickel-Tetra Collaboration on Investigational Inhaled Medical Cannabis Product Moves Forward
Tetra Bio-Pharma announced the advancement of its collaboration with Storz & Bickel for the development of a fibromyalgia treatment combining Tetra’s investigational medical cannabis product PPP001 and Storz & Bickel’s vaporizer Mighty Medic. The study protocol designed to investigate the therapy was approved by a Canadian independent ethics board, and was recently submitted for review to Health Canada, which controls medicine approval and commercialization in Canada. “The Independent Ethics Board approval represents a major step forward prior to obtaining approval from Health Canada and the clinical study will allow Tetra to accelerate bringing PPP001 for fibromyalgia patients,” Guy Chamberland, PhD, chief executive and scientific officer at Tetra Bio-Pharma, said in a press release. Tetra Bio-Pharma is a biopharmaceutical company focused on the discovery and development of cannabinoid-based therapies, as products derived from cannabis have been shown to offer pain relief. Tetra’s PPP001 is an inhaled medical cannabis product developed to treat patients with advanced cancer pain, and is being tested in Phase 2/3 trials. In July this year, Tetra announced a collaboration with Storz & Bickel to test th
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *